French National survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 virology network)
|
|
- Debra Barton
- 6 years ago
- Views:
Transcription
1 French National survey of resistance to integrase inhibitors in a context of routine hospital care (ANRS AC11 virology network) Marcelin AG ; Grude M; Charpentier C; Bellecave, P; Le Guen, L; Pallier, C; Raymond, S; Mirand, A ; Bocket, L; Morand-Joubert, L; Delaugerre, C ; Montes, B; Jeulin, H; Mourez, T; Fafi-Kremer, S; Amiel, C ; Roussel, C ; Dina, J; Trabaud, MA ; Le Guillou-Guillemette, H ; Valet, S ; Signori-Schmuck, A ; Maillard, A; Krivine, A; Flandre, P; Descamps, D; Calvez, V Presentation Number: Abst#_O_#03 Pr Anne-Geneviève Marcelin Laboratoire de Virologie Hôpital Pitié-Salpêtrière France
2 Presenter Disclosure Information AG Marcelin has no commercial interests. AG Marcelin has received travel grants, honoraria, and study grants from various pharmaceutical companies including Gilead Sciences, Merck-Sharp & Dohme-Chibret, Janssen-Cilag and ViiV Healthcare.
3 Background Integrase inhibitors (INI) are the latest antiretrovirals introduced in clinical practice and are becoming widely used. INI (RAL, EVG and DTG) resistance have been extensively studied in vitro and in clinical trials and with limited number of failures. There is a need to get more data about resistance to compounds of this class in clinical setting. 3
4 Objectives of the study Multicenter, observational study Primary objective: To characterize resistance patterns in case of virological failure to integrase inhibitor-based regimen in clinical setting from the french ANRS network Secondary objectives: To identify factors associated with selection of INI resistance mutations To identify new INI associated resistance mutations 4
5 Patients and methods Inclusion criteria HIV-1 infected patient Failing an integrase inhibitor-based regimen (RAL, EVG, DTG) Virological failure confirmed if 2 consecutive plasma VL 50 cp/ml (01/01/ /12/2017) Patients followed in clinical sites within the ANRS AC11 resistance sentinel network Genotypic resistance The sequences of the protease, reverse transcriptase (RT) and integrase genes were performed in each Virology laboratory, using the ANRS consensus technique (2 nd plasma sample). Resistance tests were interpreted according to the last ANRS genotypic algorithm ( 5
6
7 Resistance Possible resistance
8 Population characteristics (n = 513) Variable Median (IQR) Age, years 48.6 [ ] Sex, male (%) 341 (66) Naive, n (%) 53 (10.3) Time since HIV-1 diagnosis, years 16.7 [ ] Duration of current INI regimen, years 0.9 [ ] Nadir CD4 cell count, mm [33-276] CD4 cell count at initiation, mm [ ] CD4 cell count at failure, mm [ ] viral load at initiation (Log 10 cp/ml) 3.1 [ ] viral load at failure (Log 10 cp/ml) 2.9 [2.3-4] HIV-1 subtype B (%) 289 (56.3) 8
9 Percentage (%) ARV treatment at time of failure (n = 513)
10 INIs resistance-associated mutations at failure 58 % of virological failures: no INIs resistance mutations 42 % of virological failures: presence of at least 1 INI mutation 25 % with 1 mutation 10 % with 2 mutations 7 % of with >2 mutations
11 Percentage (%) % of INIs genotypic resistance at failure N = 285 N = 122 N = 106 High frequency of resistance selected by RAL and EVG with cross resistance Less resistance selected by DTG
12 % of INI resistance mutations Factors associated with INIs mutations Frequency of INIs mutations at time of testing significantly associated with failure VL (Odd Ratio = 1.3 per 1 log 10 copies/ml increase) <2 LOG 2-3LOG >3 LOG Viral Load Failure (log c/ml) Patients failing DTG had significantly less INI resistance mutations at failure than patients failing RAL (p = 0.003) and patients failing EVG (p=0.001)
13 Patients failing a first line regimen (n = 53) Variable Median (IQR) Age, years 43.3 [32.2 ; 52.6] Sex, male (%) 35 (66) Time since HIV-1 diagnosis, years 2.2 [0.6 ; 8.0] Duration of current INI regimen, years 0.9 [0.5 ; 2.7] Nadir CD4 cell count, mm [38 ; 303.5] CD4 cell count at initiation, mm [77.5 ; 358] CD4 cell count at failure, mm [200 ; 620] viral load at initiation (Log 10 cp/ml) 5.1 [3.8 ; 5.5] viral load at failure (Log 10 cp/ml) 3 [2.2 ; 4.2] HIV-1 subtype B 21 (40)
14 Patients failing a first line regimen (RAL, n = 31) At failure 8/31 (26%) patients had INI resistance mutations - 1 with emergent mutations: 1 T97A - 7 with no baseline genotype: 3 L74I, 1 92Q + 1 N155H, 1 T97A + 1 N155H + 1 E157Q, 1 E138K, 1 N155H 5/31 (16%) had M184V (4 alone and 1 with INI mutation)
15 Patients failing a first line regimen (EVG, n = 16) At failure 6/16 (37.5%) patients had INI resistance mutations : - 5 with emergent mutations: 1 T66I ; 1 E92Q + 1 S153Y + 1 N155H ; 2 N155H, 1 E92Q + 1 E157Q - 1 with no baseline genotype: L74I + P145S 5/16 (31%) had M184V always with INI mutations
16 Patients failing a first line regimen DTG (n = 6) At failure: 0/6 patients had INI emergent resistance mutations at failure - 2/6 patients had INI mutations at baseline: 1 L74I, 1 E157Q 0/6 patients had M184V
17 Conclusions (1) Large cohort of patients (n = 513) failing INI-based regimens (RAL, EVG, DTG) followed in hospital clinical care Among patients failing an INI-based regimen, 42% harbored viruses with at least 1 INI resistance mutation Close to 39% in 502 patients failing RAL-based regimen (Fourati et al. JAC 2015) RAM profiles: - N155H = 16%, L74I/M = 12%, Q148HR = 8% and T97A = 7% - Y143HRC and E138AK = 3% - No R263K Among patients failing to RAL, 34% harboured a virus resistant to RAL Among patients failing to EVG, 43% harboured a virus resistant to EVG High level of cross resistance between RAL and EVG 17
18 Conclusions (2) Among all patients failing to DTG (as the first INI or in patients previously exposed to RAL or EVG) 15% harboured a virus resistant to DTG QD and 6% to DTG BID However, in patients failing to DTG when used as the first line regimen (ARV naïve patients), neither major resistance to INI, nor NRTI resistance was detected at failure. Confirm resistance robustness of DTG Ongoing studies Plasma drug levels at failure (Dr Gilles Peytavin, Bichat Claude Bernard hospital) Ultradeep sequencing at failure 18
19 ANRS AC11 Resistance Group Coordination Comittee Pr Diane Descamps Pr Vincent Calvez Dr Marie-Laure Chaix Dr Charlotte Charpentier Pr Constance Delaugerre Dr Philippe Flandre Pr Jacques Izopet Pr Anne-Geneviève Marcelin Dr Laurence Morand-Joubert Dr Gilles Peytavin Pr Jean-Christophe Plantier Dr Stéphanie Raymond Dr Catherine Tamalet Pr Sabine Yerly
20 ANRS AC11 Resistance Group Dr Evelyne Lagier Dr Catherine Roussel Dr Hélène Le Guillou Dr Dominique Bettinger Pr Hervé Fleury Dr Sandrine Reigadas Dr Pantxika Bellecave Dr Patricia Recordon-Pinson Pr Christopher Payan Dr Sophie Vallet Pr Astrid Vabret Dr Cécile Henquell Dr Audrey Mirand Dr Alexis de Rougemont Pr Francis Barin Dr Antoine Chaillon Pr Virginie Ferre Dr Elisabeth André-Garnier Pr Jacques Izopet Dr Stéphanie Raymond Dr Georges Dos Santos Pr Patrice Morand Dr Anne Signori-Schmuck Dr Laurence Bocket Dr Sylvie Ranger-Rogez Pr Patrice André Dr Jean-Claude Tardy Dr Mary-Anne Trabaud Dr Catherine Tamalet Dr Catherine Delamare Dr Brigitte Montes Pr Evelyne Schvoerer Dr Jacqueline Cottalorda Dr Jérôme Guinard Dr Aurélie Guiguon Dr Geneviève Giraudeau Dr Véronique Brodard Dr Anne Maillard Pr Jean-Christophe Plantier Dr Chantal Chaplain Pr Thomas Bourlet Dr Stéphanie Marque-Juillet Dr Chakib Alloui Dr Samira Fafi-Kremer Dr Marie-Paule Schmitt Dr Heidi Barth Pr Francoise Stoll-Keller Dr Cécile Poggi Pr Françoise Brun-Vézinet Pr Diane Descamps Dr Charlotte Charpentier Dr Benoit Visseaux Dr Lucile Larouy Gilles Collin Mélanie Bertine Dr Gilles Peytavin Dr Anne Krivine Dr Magali Bouvier Dr Marie-Laure Chaix Pr Vincent Calvez Pr Anne-Geneviève Marcelin Dr Marc Wirden Dr Cathia Soulié Dr Sidonie Lambert-Niclot Dr Isabelle Malet Dr Stéphanie Haim-Boukobza Pr Anne-Marie Roque Dr Corinne Amiel Dr Véronique Schneider Dr Coralie Pallier Dr Ali Si-Mohamed Dr Laurence Morand-Joubert Dr Constance Delaugerre Dr Véronique Avettand-Fenoel Dr Jean-Dominique Poveda Dr Sabine Yerly Dr Dominique Costagliola Dr Philippe Flandre Dr Lambert Assoumou Dr Karine Grenet Dr Frédérique Moreau
Pr Vincent Calvez Dpt of Virology Hôpital Pitié-Salpêtrière France ANRS
French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS AC11 virology
More informationAntiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma
J Antimicrob Chemother 2015; 70: 566 572 doi:10.1093/jac/dku419 Advance Access publication 25 October 2014 Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than
More informationPharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women
Pharmacokinetic, Safety and Efficacy of Darunavir/Ritonavir in HIV+ Pregnant Women DR MINH LÊ PHARMACO-TOXICOLOGY DEPARTMENT APHP, HÔPITAL BICHAT-CLAUDE BERNARD PARIS, FRANCE ABSTRACT #O_01 17TH INTERNATIONAL
More informationAbstract #8 15th EU Meeting on HIV & Hepatitis (7-9 June 2017)
Epidemiological study of Doravirine associated resistance mutations in HIV-1- infected treatment-naïve patients from two large databases in France and Italy Anne-Genevieve Marcelin, Maria Mercedes Santoro,
More informationWhat is the virological support for reduced drug regimens?
What is the virological support for reduced drug regimens? Pr Anne-Genevieve Marcelin Pitié-Salpêtrière Hospital UMR 1136 University Pierre et Marie Curie Paris, France Disclosure of Personal and Commercial
More informationPersistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated factors and virological outcome
J Antimicrob Chemother 2012; 67: 2231 2235 doi:10.1093/jac/dks191 Advance Access publication 29 May 2012 Persistent low-level HIV-1 RNA between 20 and 50 copies/ml in antiretroviral-treated patients: associated
More informationResistance to novel integrase inhibitors
Resistance to novel integrase inhibitors Dr Anne-Geneviève Marcelin Virology - Pitié-Salpêtrière Hospital INSERM U943, UPMC HIV integrase Dr Anne-Geneviève Marcelin 1 HIV Integration: A Six Step Process
More informationof Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Dr Charlotte CHARPENTIER Laboratoire de Virologie Hôpital Bichat-Claude Bernard INSERM UMR 1137- IAME Université Paris Diderot Plan 1 st generation: Raltegravir
More informationActualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis
Actualités en virologie Paris, le 6 juillet 2011 Journée scientifique de Solthis Pr Vincent CALVEZ MD, PhD Dpt of Virology Pitié-Salpêtrière Hospital Paris, France Transmitted Drug Resistance in Low and
More informationPr Vincent Calvez. Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière
Pr Vincent Calvez Faculté de Médecine Sorbonne Université UMR Sorbonne Université Inserm 1136 Service de Virologie Hôpital Pitié-Salpêtrière Pretreatment HIV Drug Resistance in the START Study Using Next
More informationNovel mutations located outside the integrase gene confer HIV-1 integrase strand-transfer inhibitors resistance.
Novel mutations located outside the integrase gene confer HIV-1 integrase strand-transfer inhibitors resistance. Dr Olivier Delelis Pr Anne-Geneviève Marcelin 1 Resistance to Anti-Integrases Raltegravir(RAL)
More informationTransmission of integrase resistance HIV
Transmission of integrase resistance HIV Charles Boucher, MD, PhD Clinical Virology, Dept. Viroscience, Erasmus Medical Center, Erasmus Universiy, The Netherlands Major resistance mutations (Stanford)
More informationReceived 22 April 2010; returned 4 July 2010; revised 20 August 2010; accepted 13 September 2010
J Antimicrob Chemother 2010; 65: 2620 2627 doi:10.1093/jac/dkq380 Advance Access publication 21 October 2010 Increasing prevalence of transmitted drug resistance mutations and non-b subtype circulation
More informationCL Vavro, 1 J Huang, 2 C Avatapally, 1 S Min, 1 and M Ait-Khaled 3. GlaxoSmithKline: 1 Research Triangle Park,NC, USA; 2 Toronto, ON, Canada; 3
Durable Efficacy and Limited Integrase Resistance Evolution in Subjects Receiving Dolutegravir After Failing Prior Integrase Inhibitor (INI) Regimens: Week 48 Results from VIKING-3 CL Vavro, 1 J Huang,
More informationResponse to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network
Short communication Antiviral Therapy 12:1305 1310 Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network Marie-Laure Chaix 1 *, Loic Desquilbet
More informationAntiviral Therapy 2012; 17: (doi: /IMP2093) UPMC Université de Paris 06, UMR_S938, INSERM, CDR Saint-Antoine, Paris, France 2
Antiviral Therapy 2012; 17:915 919 (doi: 10.3851/IMP2093) Short communication Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled
More informationAntiviral Therapy 2015; 20: (doi: /IMP2949)
Antiviral Therapy 2015; 20:655 660 (doi: 10.3851/IMP2949) Short communication Risk of virological failure in HIV-1-infected patients experiencing low-level viraemia under active antiretroviral therapy
More informationMutations to Integrase Inhibitors in real life
Mutations to Integrase Inhibitors in real life González-Domenech CM, Viciana I, Sena Corrales G, Delgado M, De la Torre J, Torres Tortosa M, Téllez F, Jarilla F, Clavijo E, Santos J BACKGROUND INSTI Block
More information9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris. Mark Mascolini
Maintenance With Raltegravir/Etravirine Strong at 48 Weeks in Older Adults - Efficacy of a Maintenance Strategy with Raltegravir/Etravirine : the ANRS 163 ETRAL trial 9th IAS Conference on HIV Science
More informationResistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762)
Resistance Post Week 48 in ART-Experienced, Integrase Inhibitor-Naïve Subjects with Dolutegravir (DTG) vs. Raltegravir (RAL) in SAILING (ING111762) MR Underwood 1, F DeAnda 1, D Dorey 2, K Hightower 1,
More informationRound table discussion Patients with multiresistant virus : A limited number, but a remarkable deal Introduction
Disclosure statement: Dr. Santoro reports personal fees from ViiV Healthcare, Gilead and JANSSEN Cilag Round table discussion Patients with multiresistant virus : A limited number, but a remarkable deal
More informationTitle: Usefulness of Kaposi sarcoma-associated herpesvirus (KSHV)-DNA viral. load in whole blood for the diagnosis and monitoring of KSHV-associated
JCM Accepted Manuscript Posted Online 11 April 2018 J. Clin. Microbiol. doi:10.1128/jcm.00569-18 Copyright 2018 American Society for Microbiology. All Rights Reserved. 1 2 3 Title: Usefulness of Kaposi
More informationClinical use of HIV-DNA quantity and resistance testing
Clinical use of HIV-DNA quantity and resistance testing Personal fees and travel grants Abbott Molecular Gilead Sciences Janssen-Cilag Merck Sharp and Dohme ViiV Healthcare Research and educational grants
More informationLow-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice
J Antimicrob Chemother 2015; 70: 2347 2353 doi:10.1093/jac/dkv099 Advance Access publication 28 April 2015 Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice
More informationINTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING
INTEGRASE INHIBITOR (INI) RESISTANCE IN HIV- POSITIVE PATIENTS UNDERGOING ROUTINE TESTING Dr. Danni Kirwan ID/Microbiology SpR St. George s Hospital, London ARV initiation in treatment-naïve patients BHIVA,
More informationVIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir in treatment-experienced subjects IL/DLG/0040/14 June 2014 GSK (Israel) Ltd. Basel 25, Petach Tikva. Tel-03-9297100 Medical information service: il.medinfo@gsk.com
More informationShort communication Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes
Antiviral Therapy 14:123 129 Short communication Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF2_AG subtypes Almoustapha-Issiaka Maïga 1, Isabelle Malet 1 *, Cathia Soulie
More informationDoes Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Does Resistance Still Matter? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosure The speaker serves as a consultant to, and has received
More informationResistance Characteristics of Integrase Inhibitors
Resistance Characteristics of Integrase Inhibitors Madrid, November 2016 Jonathan M Schapiro, MD National Hemophilia Center, Israel Stanford University School of Medicine, USA Disclaimer Presentation includes
More informationResistance to Integrase Strand Transfer Inhibitors
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Resistance to Integrase Strand Transfer Inhibitors David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases
More informationViro-Immunological Response in HIV-1 Infected Patients with Multiple. Treatment Failures Receiving Raltegravir and Optimized Background Therapy,
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Viro-Immunological Response in HIV-1 Infected Patients with Multiple Treatment Failures Receiving Raltegravir and Optimized Background
More informationHIV-2 Therapy. Ricardo Jorge Camacho KU Leuven, Rega Institute for Medical Research, Leuven, Belgium
HIV-2 Therapy Ricardo Jorge Camacho KU Leuven, Rega Institute for Medical Research, Leuven, Belgium World distribution ~1.000.000 2.000.000 people infected in West Africa Highest prevalence : Guinea-Bissau
More informationResistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Viruses 2014, 6, 2858-2879; doi:10.3390/v6072858 Review OPEN ACCESS viruses ISSN 1999-4915 www.mdpi.com/journal/viruses Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical
More informationRESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients
RESEARCH B/F/TAF in Treatment-Naïve HIV-1 and HIV-1 RNA Suppressed Switch Patients Kirsten White Gilead Sciences, Inc., Foster City, CA Background Bictegravir (BIC; B) is a novel, unboosted integrase strand
More informationReceived 2 February 2010/Returned for modification 11 March 2010/Accepted 27 May 2010
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Aug. 2010, p. 3335 3340 Vol. 54, No. 8 0066-4804/10/$12.00 doi:10.1128/aac.00148-10 Copyright 2010, American Society for Microbiology. All Rights Reserved. Evaluation
More informationVIKING STUDIES. Efficacy and safety of dolutegravir. treatment-experienced subjects
VIKING STUDIES Efficacy and safety of dolutegravir treatment-experienced subjects (DTG) in UK/DLG/0083/14e(2) Date of preparation: February 2017 Prescribing information is available at the end of this
More informationCabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results
Slide 1 Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results David A. Margolis, 1 Juan Gonzalez-Garcia, 2 Hans-Jürgen Stellbrink, 3 Joe Eron, 4 Yazdan Yazdanpanah, 5 Sandy
More informationReduced Drug Regimens
Dr. Jose R Arribas @jrarribas Financial disclosures JOSE R ARRIBAS Research Support: Speaker s Bureau: Viiv, Janssen, Abbvie, BMS, Gilead, MSD Board Member/Advisory Panel: Merck, Gilead Stock/Shareholder:
More informationVirological suppression and PIs. Diego Ripamonti Malattie Infettive - Bergamo
Virological suppression and PIs Diego Ripamonti Malattie Infettive - Bergamo Ritonavir-boosted PIs Boosted PIs: 3 drugs in one The intrinsic antiretroviral activity Viral suppression and high baseline
More informationIAC Analyst Presentation
IAC Analyst Presentation David Redfern Chairman, ViiV Healthcare Chief Strategy Officer, GSK July 27, 2012 1 ViiV Healthcare Dr Dominique Limet CEO, ViiV Healthcare July 27, 2012 2 Equity split of 85%
More informationAntiviral Therapy 6:
Antiviral Therapy 6: 179-183 Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapynaive patients receiving stavudine
More informationAIDS Research and Human Retroviruses
: http://mc.manuscriptcentral.com/aidsresearch Human immunodeficiency virus type seroprevalence and antiretroviral drug resistance-associated mutations in miners in Gabon, central Africa r Fo Journal:
More informationAntiretroviral Treatment Strategies: Clinical Case Presentation
Antiretroviral Treatment Strategies: Clinical Case Presentation Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan Chia-Jui, Yang M.D Disclosure No conflicts of interests.
More informationHIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pretreated Patients
HIV DNA Genotyping by UDS compared with cumulative HIV RNA Genotypes in Pretreated Patients Mathieu BLOT, Yannis DUFFOURD, Hélène GIRAUDON, Emilie TISSERAND, Arnaud SALMON-ROUSSEAU, Sophie MAHY, Marielle
More informationBon Usage des Antirétroviraux dans l Infection par le VIH
Bon Usage des Antirétroviraux dans l Infection par le VIH Pr. Jean-Michel Molina CHU St Louis, Assistance Publique Hôpitaux de Paris, INSERM U941 et Université Paris 7 Diderot, France 1 Liens d Intérêt
More informationDolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance.
Dolutegravir used in real-life provides high rates of virological response in conjunction with a rare emergence of integrase resistance. D. Armenia 1, V. Borghi 2, F Forbici 3, C. Gori 3, A. Bertoli 1,
More informationWhat to look for in a paper?
What to look for in a paper? D Costagliola Institut Pierre Louis d épidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, INSERM Disclosures I have received consultancy fees, honoraria,
More informationLê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group
Lê MP, 1,2 Cournil A, 3 Kouanfack C, 4 Lem S, 5 Le Gac S, 5 Delaporte E, 3 Peytavin G, 1,2 for the NAMSAL study group 1 AP-HP, Hopital Bichat, Pharmacology-Toxicology, Paris, France, 2 IAME, UMR 1137,
More informationIntegrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection
Integrase strand-transfer inhibitors primary resistance in patients with acute/recent HIV infection Juan Ambrosioni, David Nicolás, Christian Manzardo, Fernando Agüero, José Luis Blanco, Maria del Mar
More informationIntroduction. Abstract. Key words. Diego Ripamonti 1, Andrew Hill 2, Erkki Lauthouwers 3, Yvon van Delft 4 and Christiane Moecklinghoff 5 1
AIDS Reviews. Rev. 13;15:3-6 3 Time to HIV-1 RNA Suppression Below 5 copies/ml During First-Line Protease Inhibitor-Based Antiretroviral Treatment Any Impact of Residual Viremia on Treatment Success? Diego
More informationDr Marta Boffito Chelsea and Westminster Hospital, London
Dr Marta Boffito Chelsea and Westminster Hospital, London Speaker Name Statement Dr Marta Boffito has received travel and research grants from and has been an advisor for Janssen, Roche, Pfizer, ViiV,
More informationImpact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study
Impact of obesity on antiretroviral pharmacokinetics and immuno-virological response in HIV-infected patients: a case-control study Vincent Madelain, Minh Le, Karen Champenois, Charlotte Charpentier, Roland
More informationWhat is the Virologic Support for Two-Drug Regimens?
What is the Virologic Support for Two-Drug Regimens? Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting
More informationHIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract.
HIV-1-infected Males and Females under Less-Drug Regimens Achieve Antiretroviral Levels above the Inhibitory Concentration in the Genital Tract. Sandrine LEFEUVRE, Julie BOIS-MAUBLANC, Camélia GUBAVU,
More informationReduced drug regimens
Reduced drug regimens Andrea De Luca MD Dipartimento di Biotecnologie Mediche, Università di Siena Department of Internal Medicine, University Hospital, Siena, Italy Conflicts of interest Research grants
More informationReceived 31 October 2013; returned 10 November 2013; revised 16 December 2013; accepted 19 December 2013
J Antimicrob Chemother 2014; 69: 1648 1652 doi:10.1093/jac/dkt536 Advance Access publication 16 February 2014 Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients
More informationAnumber of clinical trials have demonstrated
IMPROVING THE UTILITY OF PHENOTYPE RESISTANCE ASSAYS: NEW CUT-POINTS AND INTERPRETATION * Richard Haubrich, MD ABSTRACT The interpretation of a phenotype assay is determined by the cut-point, which defines
More informationPrevalence of Transmitted Drug Resistance Mutations among Naive HIV-infected patients ( ) in Northwest Spain
Prevalence of Transmitted Drug Resistance Mutations among Naive HIV-infected patients (2014-2016) in Northwest Spain Berta Pernas 1, Andrés Tabernilla 1, Marta Grandal 1, Angelina Cañizares 2, Sofía Ortún
More informationIntroduction to HIV Drug Resistance. Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School
Introduction to HIV Drug Resistance Kevin L. Ard, MD, MPH Massachusetts General Hospital Harvard Medical School Objectives 1. Describe the epidemiology of HIV drug resistance in sub-saharan Africa. 2.
More informationAcquired INSTI Resistance. Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Acquired INSTI Resistance Daniel R. Kuritzkes, M.D. Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Disclosures The speaker has received consulting honoraria, speaker
More informationReal Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort
Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort Yagci-Caglayik D 1, Gokengin D 2, Inan A 3, Ozkan-Ozdemir H 4, Inan D 5, Akbulut A 6, Korten V 1,
More informationUpdate on HIV Drug Resistance. Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School
Update on HIV Drug Resistance Daniel R. Kuritzkes, MD Division of Infectious Diseases Brigham and Women s Hospital Harvard Medical School Learning Objectives Upon completion of this presentation, learners
More informationAsier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France
Infection à VIH : une rémission possible Asier Sáez-Cirión, PhD Unité de Régulation des Infections Rétrovirales Institut Pasteur, Paris, France Viral reservoirs persist in HIV-infected individuals receiving
More informationREASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE
REASONS FOR DISCONTINUATION OF DUAL THERAPY WITH DOLUTEGRAVIR AND RILPIVIRINE R. Montejano, N. Stella-Ascariz, S. Garcia-Bujalance, JI. Bernardino, V. Hontañon, R. Mican, Montes M, E. Valencia, J. González,
More informationOriginal article Pharmacokinetics, safety and efficacy of ritonavir boosted atazanavir (300/100 mg once daily) in HIV 1-infected pregnant women
Antiviral Therapy 2015; 20:507 513 (doi: 10.3851/IMP2936) Original article Pharmacokinetics, safety and efficacy of ritonavir boosted atazanavir (300/100 mg once daily) in HIV 1-infected pregnant women
More information14 TH EUROPEAN HIV & HEPATITIS MEETING Abst#_O_06
14 TH EUROPEAN HIV & HEPATITIS MEETING 2016 Abst#_O_06 Patients with pre-existent NRTI- and NNRTI-resistance have a higher risk to lose virological suppression under tenofovir/emtricitabine/rilpivirine
More informationDisclosures. Introduction to ARV Drug Resistance New Clinicians Workshop 12/9/16. Introduction. ARS Question
Disclosures Introduction to ARV Drug Resistance New Clinicians Workshop I have no disclosures Susa Coffey, MD Division of HIV, ID and Global Medicine ARS Question Which resistance test do you order for
More informationThe Danish HIV Cohort Study, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark 4
Antiviral Therapy 2009 14: 995 1000 (doi: 10.3851/IMP1412) Original article The incidence rate of HIV type-1 drug resistance in patients on antiretroviral therapy: a nationwide population-based Danish
More informationDrug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Chilean Patients. Frequency and evolution between the years 2013 and 2016.
Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Chilean Patients. Frequency and evolution between the years 2013 and 2016. Sidgman F. 1, Valdés F. 1, Ferrer P. 2, Maureira V. 1, Afani
More informationWhole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy
Whole genome deep sequencing of HIV reveals extensive multi-class drug resistance in Nigerian patients failing first-line antiretroviral therapy K El Bouzidi 1,, RP Datir 1, V Kwaghe 3, S Roy 1, D Frampton
More informationVirological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication
Virological failure to Protease inhibitors in Monotherapy is linked to the presence of signature mutations in Gag without changes in HIV-1 replication Oscar Blanch-Lombarte Rome, 7-9 June, 2017 European
More informationTransmitted and Acquired HIV Drug Resistance in Latin America. Dr. Luis Enrique Soto Ramírez MEXICO
Transmitted and Acquired HIV Drug Resistance in Latin America Dr. Luis Enrique Soto Ramírez MEXICO Disclosure Advisory boards and speaker for: Abbvie GSK/ViiV MSD Roche Diagnostics OVERVIEW The development
More informationHIV Treatment: New and Veteran Drugs Classes
HIV Treatment: New and Veteran Drugs Classes Jonathan M Schapiro, MD National Hemophilia Center Stanford University School of Medicine Rome, March 2013 Overview Many excellent antiretroviral agents are
More informationSecond-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Second-Line Therapy David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, Division of Infectious Diseases University of Washington Presentation
More informationManagement of ART Failure. EACS Advanced HIV Course 2015 Dr Nicky Mackie
Management of ART Failure EACS Advanced HIV Course 2015 Dr Nicky Mackie Outline Defining treatment success Defining treatment failure Reasons for ART failure Management of ART failure Choice of second
More informationTenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study
Abstract O_03 Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study M.P. Lê Pharmacy Resident Clinical Pharmacology
More informationHIV Drug Resistance: An Overview
Human Journals Review Article October 2015 Vol.:1, Issue:1 All rights are reserved by Suraj Narayan Mali et al. HIV Drug Resistance: An Overview Keywords: HIV drug resistance mechanism, Antiretroviral
More informationIn vitro Phenotypic Susceptibility of HIV-2 Clinical Isolates to Protease Inhibitors ACCEPTED
AAC Accepts, published online ahead of print on 28 January 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.01284-07 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationAntiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V
Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog Mutation(s) and M184V Christian Callebaut, PhD Gilead Sciences, Foster City, CA, USA HIV DART AND EMERGING VIRUSES 12/08/2016
More informationIntegrase Strand Transfer Inhibitors on the Horizon
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Integrase Strand Transfer Inhibitors on the Horizon David Spach, MD Clinical Director, Northwest AETC Professor of Medicine, University of Washington Presentation
More informationSINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
SINGLE Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects SE/HIV/0023/14 January 2014 PHASE III DTG TRIALS IN TREATMENT-NAÏVE ADULT SUBJECTS WITH HIV SINGLE 1 N=833 Phase III non-inferiority,
More informationEuropean Guidelines. for the Clinical Management and Treatment of HIV Infected Adults
European Guidelines for the Clinical Management and Treatment of HIV Infected Adults 2005 These Euroguidelines result from the comparison of guidelines from several European countries and from a discussion
More informationDisclosure. Relations that could be relevant for the meeting
HIV drug resistance A.M.J. Wensing, MD, PhD Senior Consultant Virology, University Medical Center, Utrecht Honorary Professor, University of Witwatersrand, Johannesburg Disclosure Relations that could
More informationIAS 2013 Towards an HIV Cure Symposium
In chronically HIV-1-infected patients long-term antiretroviral therapy initiated above 500 CD4/mm 3 achieves better HIV-1 reservoirs' depletion and T-cell count restoration IAS 2013 Towards an HIV Cure
More informationSeptember Version n 25
ANRS - AC 11: RESISTANCE GROUP GENOTYPE INTERPRETATION: NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS ZDV Mutations associated with resistance Mutations associated with «possible resistance»
More informationDOI: /hiv British HIV Association HIV Medicine (2014), 15, SHORT COMMUNICATION
DOI: 10.1111/hiv.12071 SHORT COMMUNICATION Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load 100 000 copies/ml in the pooled ECHO and THRIVE phase 3, randomized,
More informationSpontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established?
HIV/AIDS BRIEF REPORT Spontaneous Control of Viral Replication during Primary HIV Infection: When Is HIV Controller Status Established? Cécile Goujard, 1,2 Marie-Laure Chaix, 3 Olivier Lambotte, 1,2 Christiane
More informationInfezione da HIV: Possibilità di eradicazione. Claudia Alteri
Infezione da HIV: Possibilità di eradicazione Claudia Alteri Definitions Residual viremia: Persistent HIV-RNA measured in plasma at levels below the limit of detection of the standard clinical assay Viral
More informationClinical Management of Resistance. AMJ Wensing, MD, PhD
Clinical Management of Resistance AMJ Wensing, MD, PhD Changing treatment paradigm First Line Second Line? New First Line North America Western Europe: Eastern Europe Africa mix South America mix More
More informationSECONDARY OBJECTIVES:
Study No.: 112 419 Title: Retrospective study using the NADIS database of the reasons for discontinuing the Abacavir-Lamivudine combination in HIV-infected patients treated by an antiretroviral regimen
More informationDr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa
Dr Carole Wallis, PhD Medical Director, BARC-SA Head of the Specialty Molecular Division, Lancet Laboratories, South Africa Transmitted drug resistance Resistance patterns in first-line failures in adults
More information2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012
2 nd Line Treatment and Resistance Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012 Overview Basics of Resistance Treatment failure Strategies to manage treatment failure Mutation Definition: A change
More informationOptimizing the treatment
PIs are the real world answer for: Optimizing the treatment Sergio Lo Caputo Malattie Infettive - Azienda Sanitaria Firenze Evolution of ARVs DARUNAVIR PI ETRAVIRINA NNRTI DOLUTEGRAVIR INI POTENZA E ALTA
More informationReceived 26 November 2009; returned 28 December 2009; revised 15 January 2010; accepted 18 January 2010
J Antimicrob Chemother 21; 65: 741 748 doi:1.193/jac/dkq35 Advance publication 18 February 21 Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary
More informationHIV replication and selection of resistance: basic principles
HIV replication and selection of resistance: basic principles 26th International HIV Drug Resistance and Treatment Strategies Workshop Douglas Richman 6 November 2017 CLINICAL DATA DURING SIXTEEN WEEKS
More informationVirological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA Study)
Original article Antiviral Therapy 13:271 279 Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA Study) Isabelle Pellegrin 1 *, Linda Wittkop
More informationThe ANRS CO22 Hepather cohort is conducted in collaboration with AFEF and supported by MSD, Janssen, Gilead, BMS, Roche, Abbvie.
Safety and Efficacy of the Combination Daclatasvir-Sofosbuvir in HCV Genotype 1-Mono-Infected Patients from the French Observational Cohort ANRS CO22 Hepather Stanislas Pol, Marc Bourliere, Sandy Lucier,
More information2.0 Synopsis. Kaletra FRAN Clinical Study Report R&D/ (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Title of Study: A Pilot, Open-Label, Randomized, Comparative Study of the Antiviral Efficacy of Lopinavir /Ritonavir Single-Drug Regimen versus Lopinavir /Ritonavir in Combination with Lamivudine/Zidovudine
More informationScottish Medicines Consortium
Scottish Medicines Consortium raltegravir, 400mg film-coated tablet (Isentress) No. (461/08) Merck, Sharp and Dohme Limited 04 April 2008 The Scottish Medicines Consortium has completed its assessment
More informationClinical skills building - HIV drug resistance
Clinical skills building - HIV drug resistance Richard Lessells Clinical case 44-year old HIV-positive male HIV diagnosis 2010 Pre-treatment CD4+ count not known Initiated first-line ART (TDF/FTC/EFV)
More information